PaxMedica, Inc. Common Stock
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Howard J. Weisman
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 303 South Broadway Tarrytown NY United States of America 10591
- IPO Date
- Aug 26, 2022
- CIK
- 0001811623
- Website
- paxmedica.com
- Similar Companies
- Business
- PaxMedica, Inc. PaxMedica, Inc. (PXMD) is a clinical-stage biopharmaceutical company focused on developing anti-purinergic drug therapies for disorders with intractable neurologic symptoms, including autism spectrum disorder, fragile X-associated tremor/ataxia syndrome, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome and human African trypanosomiasis. The company's lead product candidate, PAX-101, comprises an intravenous formulation of suramin in Phase 3 clinical trials for these indications; PAX-102 consists of an intranasal formulation of suramin for neurologic conditions; and additional candidates target selective antagonists of purine receptor subtypes along with PAX-HAT-301 specifically for human African trypanosomiasis treatment. Founded in 2018 and headquartered in Tarrytown, New York, PaxMedica operates primarily in the United States with global ambitions to address unmet needs in neurodevelopmental and neglected tropical diseases through clinical development and planned regulatory submissions. In recent developments, the company acquired suramin research assets from Rediscovery Life Sciences in 2023 to support its New Drug Application for PAX-101 in human African trypanosomiasis, targeting a filing in 2024 with potential eligibility for an FDA Priority Review Voucher; it continues advancing PAX-101 toward NDA submission for autism spectrum disorder amid a transition off the Nasdaq exchange while preparing for key FDA meetings.
ProMetic Life Sciences (OTCMKTS:PFSCF) & PaxMedica (NASDAQ:PXMD) Financial Contrast
Analyzing PaxMedica (NASDAQ:PXMD) and Leap Therapeutics (NASDAQ:LPTX)
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
PaxMedica Secures Immediate Exercise of Warrants
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
Choosing Unknown Penny Stocks, 3 Top Tips
Why is PaxMedica (PXMD) stock surging today?
Why is PaxMedica (PXMD) stock surging today?
Why Is PaxMedica (PXMD) Stock Up 93% Today?
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
PaxMedica Announces Closing of $7.0 Million Public Offering
Why Are Stocks Up Today?
Penny Stocks To Buy? 5 To Watch Right Now
Why Is PaxMedica (PXMD) Stock Up 57% Today?
Why Is PaxMedica (PXMD) Stock Down 40% Today?